• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.

作者信息

Schjesvold Fredrik, Richardson Paul G, Facon Thierry, Alegre Adrián, Spencer Andrew, Jurczyszyn Artur, Sunami Kazutaka, Frenzel Laurent, Min Chang-Ki, Guillonneau Sophie, Lin Peggy L, Le-Guennec Solenn, Campana Frank, Van de Velde Helgi, Bensfia Samira, Bringhen Sara

机构信息

Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.

Dana-Farber Cancer Institute, Boston, MA, USA.

出版信息

Haematologica. 2022 Mar 1;107(3):774-775. doi: 10.3324/haematol.2021.279160.

DOI:10.3324/haematol.2021.279160
PMID:35229573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8883557/
Abstract
摘要

相似文献

1
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤老年患者：ICARIA-MM亚组分析
Haematologica. 2022 Mar 1;107(3):774-775. doi: 10.3324/haematol.2021.279160.
2
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.依既往治疗线数和难治状态分层的复发/难治性多发性骨髓瘤患者中伊沙佐米联合泊马度胺和地塞米松治疗：ICARIA-MM 亚组分析。
Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.
3
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.ICARIA-MM 研究中伴有高危细胞遗传学的复发/难治性多发性骨髓瘤患者的亚组分析。
Br J Haematol. 2021 Jul;194(1):120-131. doi: 10.1111/bjh.17499. Epub 2021 May 25.
4
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
5
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性老年多发性骨髓瘤患者：ICARIA-MM亚组分析
Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
6
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤虚弱患者：ICARIA-MM亚组分析
Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23.
7
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.依沙佐米昔单抗治疗复发/难治性多发性骨髓瘤：III 期 ICARIA-MM 研究关键亚组分析综述。
Future Oncol. 2021 Dec;17(34):4797-4812. doi: 10.2217/fon-2021-0568. Epub 2021 Sep 15.
8
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.依沙佐米-泊马度胺-地塞米松对比泊马度胺-地塞米松用于治疗东亚复发/难治性多发性骨髓瘤患者：ICARIA-MM 亚组分析。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e751-e761. doi: 10.1016/j.clml.2022.04.005. Epub 2022 Apr 8.
9
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.依沙替康单抗联合泊马度胺/地塞米松与泊马度胺/地塞米松治疗复发/难治性多发性骨髓瘤的 ICARIA Ⅲ期研究设计。
Future Oncol. 2018 May;14(11):1035-1047. doi: 10.2217/fon-2017-0616. Epub 2017 Dec 22.
10
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.isatuximab、卡非佐米和地塞米松用于复发多发性骨髓瘤（IKEMA）：一项多中心、开放标签、随机3期试验
Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.

引用本文的文献

1
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma.如何管理来那度胺难治性多发性骨髓瘤患者。
Cancers (Basel). 2022 Dec 27;15(1):155. doi: 10.3390/cancers15010155.
2
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.单克隆抗体及抗体药物偶联物在多发性骨髓瘤中的应用
Cancers (Basel). 2021 Mar 29;13(7):1571. doi: 10.3390/cancers13071571.
3
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.单克隆抗体在新诊断的不适于移植的多发性骨髓瘤患者一线治疗中的作用
Pharmaceuticals (Basel). 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020.
4
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.单克隆抗体：复发/难治性多发性骨髓瘤治疗中的主角
Pharmaceuticals (Basel). 2020 Nov 27;13(12):426. doi: 10.3390/ph13120426.
5
Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients.老年中晚期多发性骨髓瘤患者管理中的诊断与治疗挑战
Cancers (Basel). 2020 Oct 24;12(11):3106. doi: 10.3390/cancers12113106.